Exploring PROTACs in drug discovery and development

Proteolysis targeting chimeras (PROTACs) are able to degrade disease-causing proteins by hijacking the cells own degradation pathway. These molecules are therefore changing the drug discovery landscape by enabling targeting for previously 'undruggable' proteins.

Explore advanced LC-MS bioanalytical solutions that can support your PROTAC workflow to confidently quantify and accelerate development with sensitivity, selectivity and reproducibility.